Clinical Proteomics

Editors OverviewPART 1: TECHNOLOGIESPre-analytical issues in clinical proteomic studiesProtein separation by 2DEProtein separation : liquid chromatographyHPLC in protein discoveryIEF analysis of peptides for biomarkers analysisCapillary electrophoresis separations for clinical proteomics Quantitative proteomics using nanoLC with high accuracy mass spectrometryAntibody microarrays for protein and glycan detectionBiomarker Identification: The Role of Experimental Design, Statistics, and Data SharingPART 2: CANCERApplications of stable isotope tagging based quantitive proteomics in cancer research2-D liquid seperations, protein microarrays and mass spectrometry in comprehensive analysis of PTM and biomarker discoveryDevelopment and Use of Reversed-Phase Protein Microarrays for Clinical ApplicationsCDK1 and cancer: usefulness of proteomic approaches in assesment of the molecular mechanisms and efficacy of novel therapeuticsPART 3: CARDIOVASCULAR DISEASEDiagnostic markers for monitoring heart transplant rejectionThe study of microheterogeneity in human plasma proteins: applications to acute myocardial infarctionDiscovery of biomarkers for cardiovascular diseasesDevelopment of biomarker Developfment Pipeline: Search for Myocardial Ischemia BiomarkersAlbuminome as a tool for biomarker discoveryPART 4: VASCULAR DISEASESApplication of Metabolomics to Cardiovascular Biomarker and Pathway DiscoveryUrinary biomarkers in diabetic nephropathy and other glomerular diseases Pulmonary proteomicsProteomics providing insights into major psychiatric disordersPART 6: BIOMARKERSRedox Proteomics Analysis of Oxidative Modified Brain Proteins in Alzheimer´s Disease and Mild Cognitive Impairment: Insights into the Progression of This Dementing DisorderToxicoproteomics: correlating tissue and serum proteins in liver injuriesBiomarkers for renal disease and uraemic toxinsHIV and other viral screens PART 6: AUTOANTIBODIES AND SIGNATURE BIOMARKERSApplication of Fungal Cyclic Peptides and

Jennifer Van Eyk is the Director of the Hopkins National Heart, Lung, and Blood Institute (NHLBI) Proteomics Center at Johns Hopkins University in Baltimore, Maryland. She was previously a group leader in the department of physiology at Queens University, Kingston (Canada) where she developed novel methods to investigate the reasons for heart failure and coronary artery disease. In 2000, she was awarded the Canadian Premier's Research Excellence Award.

Michael Dunn was recently appointed as Professor of Biomedical Proteomics at University College, Dublin (Ireland), where he is doing proteomics research in the areas of cardiovascular disease, transplantation and neurological disease. Prior to his move to Dublin, he was Professor of Proteomics at the Institute of Psychiatry, King's College London.

Dr. Dunn is the current President of the British Society for Proteome Research and the Editor-in-Chief of the journal Proteomics. He is also a founder Council Member of the Human Proteome Organisation (HUPO) and a member of the Executive Committee of the HUPO Brain Proteome Project (BPP).

"Das Buch zeigt in einer sehr eindrucksvollen Gesamtschau, dass die Proteomik ein interessanter Ansatz ist, um die Diagnostik und Therapie zu verbessern.?Pharmazie in unserer Zeit Februar 2008"Eine Zusammenstellung des aktuellen Wissenstands gibt das kürzlich erschienene Buch"Pharmazie in unserer Zeit, Februar 2008

"The editors have assembled 136 authors, all leaders in the field, to contribute 34 chapters outlining collective knowledge that has been gained over the last several years into a single resource book. This book is a description of science in the making." ( Journal of Tropical Pediatrics , February 2009)